Kymab Ltd., of Cambridge, U.K., and Heptares Therapeutics, of Hertfordshire, U.K., part of the Sosei Group Corp., formed a collaboration to discover, develop and commercialize antibody therapeutics, which will target G protein-coupled receptors and focus on immuno-oncology. Under the terms, Heptares will use its Star platform and Kymab will utilize its Kymouse platform to combine antibodies with antigens. The two companies will share all costs involved. Financial details were not disclosed.